Why the study?
Do PPAR-γ activators (thiazolidinediones) reduce cardiovascular morbidity and mortality?
Do PPAR-γ activators (thiazolidinediones) reduce cardiovascular morbidity and mortality?
Answers are grounded in this paper and cite their sources.
Despite favorable metabolic and vascular effects, thiazolidinediones lack conclusive evidence for reducing cardiovascular events, highlighting the need for ongoing trials to clarify their therapeutic role.
Peroxisome proliferator-activated receptor γ (PPAR-γ) is a key regulator of fatty acid metabolism, promoting its storage in adipose tissue and reducing circulating concentrations of free fatty acids. Activation of PPAR-γ has favorable effects on measures of adipocyte function, insulin sensitivity, lipoprotein metabolism, and vascular structure and function. Despite these effects, clinical trials of thiazolidinedione PPAR-γ activators have not provided conclusive evidence that they reduce cardiovascular morbidity and mortality. The apparent disparity between effects on laboratory measurements and clinical outcomes may be related to limitations of clinical trials, adverse effects of PPAR-γ activation, or off-target effects of thiazolidinedione agents. This review addresses these issues from a clinician's perspective and highlights several ongoing clinical trials that may help to clarify the therapeutic role of PPAR-γ activators in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: